GlassScriptPhysician profile
Maria Sanchez
NPI 1609412766
$882.15
in general payments reported to CMS, 2019-2025
14 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2024: $19.75 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.28 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.90 | 2025 | Jardiance |
| Amgen INC. | $172.14 | 2025 | Evenity |
| Astrazeneca Pharmaceuticals LP | $137.02 | 2022-2024 | |
| Lilly USA, LLC | $72.28 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $48.42 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $45.65 | 2025 | |
| Tandem Diabetes Care, INC. | $43.48 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $38.53 | 2025 | |
| Medtronic, INC. | $33.79 | 2025 | Minimed 780g |
| Averitas Pharma INC. | $30.17 | 2025 | Qutenza |
| Rhythm Pharmaceuticals, INC. | $29.61 | 2025 | Imcivree |
| Ascendis Pharma Endocrinology INC | $20.40 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $19.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.